文献速递其他结缔组织病

泰它西普附加治疗难治性特发性炎性肌病:一项先导研究的启示

Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该先导研究纳入11例接受泰它西普(每周160 mg)附加治疗至少3个月的成人特发性炎性肌病患者,按ACR/EULAR标准所有患者均有改善,泼尼松剂量从基线27.05(12.47)mg降至末次访视12.05(7.32)mg(P<0.005),MMT-8评分从109.18(14.18)升至137.64(15.28)(P<0.005),肌酸激酶从2670.27(2675.00)U/l降至561.09(754.09)U/l(P<0.05)。

要点

  • 11例难治性特发性炎性肌病患者接受泰它西普每周160 mg附加治疗至少3个月。
  • 按ACR/EULAR标准所有患者均获得改善,泼尼松剂量从27.05(12.47)mg降至12.05(7.32)mg(P<0.005)。
  • MMT-8评分从109.18(14.18)升至137.64(15.28)(P<0.005),肌酸激酶从2670.27(2675.00)U/l降至561.09(754.09)U/l(P<0.05)。

核心结论

  • 泰它西普在治疗难治性炎性肌病中显示出有效性,使患者激素剂量显著降低。
  • 这些发现凸显泰它西普作为特发性炎性肌病治疗中有价值选择之一的潜力。

研究设计与样本

  • 本研究纳入2023年1月至2024年1月期间在常规治疗基础上接受泰它西普治疗至少3个月的成人特发性炎性肌病患者。
  • 共纳入11例接受泰它西普(每周160 mg)治疗的患者。
  • 临床反应依据ACR/EULAR总改善评分中最小、中度与重大改善标准判定,疾病活动度采用核心组指标监测,肌炎损伤采用既定评估工具评估,肌肉功能采用八组肌群徒手肌力测试(MMT-8)评估。

主要发现

  • 治疗后评估显示,按ACR/EULAR标准所有患者均有改善。
  • 泼尼松剂量从基线至末次访视显著降低,由27.05(12.47)mg降至12.05(7.32)mg(P<0.005)。
  • MMT-8评分从109.18(14.18)升至137.64(15.28)(P<0.005)。
  • 肌酸激酶水平从2670.27(2675.00)U/l降至561.09(754.09)U/l(P<0.05)。

临床怎么用

  • 作者认为,泰它西普在难治性炎性肌病治疗中显示出有效性,并使患者激素剂量显著降低。
  • 作者认为,这些发现凸显泰它西普作为特发性炎性肌病治疗中有价值选择之一的潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to evaluate the therapeutic efficacy of telitacicept based on the conventional treatment in adults with idiopathic inflammatory myopathy (IIM), focusing on its impact on clinical manifestations. METHODS: IIM patients who had been treated with telitacicept for at least 3 months based on the conventional treatment from January 2023 to January 2024 were included in this study. The clinical response to telitacicept was determined based on the ACR/EULAR criteria for minimal, moderate and major improvement in the Total Improvement Score. Disease activity was monitored using core set measures, while myositis damage was assessed with established assessment tools. The Manual Muscle Test for eight muscle groups (MMT-8) was used to assess the muscle performance. RESULTS: A total of 11 patients administered with telitacicept (160 mg per week) were included in this study. Post-treatment assessments revealed improvements in all patients according to ACR/EULAR criteria. Notably, there was a significant reduction in the prednisone dosage from baseline to last visit [27.05 (12.47) to 12.05 (7.32) mg; P < 0.005]. An enhancement was observed in the MMT-8 score [which improved from 109.18 (14.18) to 137.64 (15.28); P < 0.005], and there was a reduction in creatine kinase level [from 2670.27 (2675.00) to 561.09 (754.09) U/l; P < 0.05]. CONCLUSION: Telitacicept demonstrated effectiveness in treating refractory inflammatory myopathy, contributing to a significant reduction in steroid dosage among the patients. These findings highlight the potential of telitacicept as a valuable therapeutic option in the management of IIM.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Gao H, Lin J, Yang M, et al. Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study. Rheumatology (Oxford). 2025. PMID: 39495163. doi:10.1093/rheumatology/keae601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。